O
OcuTerra Therapeutics
Developing a novel eye drop, designed to treat diabetic eye disease
About OcuTerra Therapeutics
OcuTerra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative drugs to treat ophthalmic diseases. The company's flagship product, OTT166, is a novel topical integrin inhibitor eye drop designed to transform the standard of care for conditions such as diabetic retinopathy. OcuTerra primarily serves patients suffering from debilitating eye diseases, aiming to provide more effective and less invasive treatment options compared to current standards. Operating in the ophthalmology market, the company leverages its extensive expertise in biotechnology and drug development to bring cutting-edge solutions to eye care. The business model revolves around advancing its drug pipeline through clinical trials, securing regulatory approvals, and eventually commercializing its products. Revenue generation is expected to come from the sales of these innovative treatments once they reach the market. The company is supported by a team of experienced leaders and advisors in the fields of biotechnology and ophthalmology, ensuring a strong foundation for its ambitious goals.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Dec 2023 | $6.7M | $175M | Undisclosed | ↗ |
| SERIES BOther financing | Nov 2021 | $35M | $140M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for OcuTerra Therapeutics is 850 monthly website visits, down 15% over the last three months. OcuTerra Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
OcuTerra Therapeutics in the Boston ecosystem
The OcuTerra Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about OcuTerra Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OcuTerra Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










